Mubadala Bio Unveils New Oncology Medicines Manufacturing Facility

Mubadala Bio has proudly inaugurated a state-of-the-art high-potency manufacturing facility within its subsidiary, Bioventure Healthcare, alongside the introduction of three vital oncology medicines. Notably, some of these treatments are being produced locally in the UAE as branded generics for the very first time. This initiative bolsters the nation’s efforts to reinforce its pharmaceutical sector and ensure reliable access to essential treatments.

This new facility, designed specifically for the safe production of high-potency medications such as cancer and hormone treatments, adheres to the highest international safety and quality standards. It is fully equipped to handle complex and sensitive products integral to advanced medical care.

The inaugural medicines launched from this facility comprise Lenalidomide, used in treating myeloma; Pomalidomide, now locally manufactured in the UAE for the first time to manage multiple myeloma; and Sunitinib, a targeted therapy effective for various advanced cancers. These medications are widely recognized as crucial components of cancer treatment.

By localizing the production of these drugs, Mubadala Bio is enhancing drug security across the UAE. This initiative supports a reliable supply of vital treatments, minimizes reliance on imports, and provides more cost-effective options for patients and healthcare professionals nationwide.

Mubadala Bio's senior officials emphasize that this pioneering step fuels the growth of the UAE's life sciences landscape. They highlighted that investments in local manufacturing expand access to critical medicines, improve health outcomes, and fortify the national medical supply chain. This project underscores Mubadala Bio’s steadfast commitment to fostering a robust and sustainable healthcare framework in the UAE.